A source of information
that few know exists

Members get the change to define and prioritize the most pressing challenges we want to tackle, as well as influence how we tackle them. Among the critical challenges your peers want to address include:


Transitioning from animal to human models in the progression of TPD drugs through the clinic


Knowing what new class of targets have the greatest potential for TPD drug development


The development of molecular glues compared to PROTACs


Methodologies to find E3 ligases


Optimizing In Vivo profiling to predict what will happen in humans


Challenges around the primary modality of degradation


The scientific parameters around how degraders work

Innovation doesn't happen in isolation

Searchlight makes meaningful progress

Bayer - A Targeted Protein Degradation_ Searchlight member“Success stories get presented at conferences but comparing notes and experiences around what didn’t work and getting ideas & input around specific questions is where the real value lies. This network offers a rare and vital chance for us to get exactly that insight.”

Proteovant Therapeutics

“This network is worthwhile because it facilitates community connection and scientific exchange to find answers to the toughest questions together – benefiting our community and our patients.”

“Usually, we hear about the 1% of things that worked, this network presents the golden opportunity to hear about the 99% of things that didn’t.”

Searchlight - LEAP HR - Exec Summary lock up (2)

Membership brochure

For more information on what’s included as part of the Targeted Protein Degradation: Searchlight membership, please download the membership brochure. 

Here’s what you’ll learn more about: 

  • The unique mission and purpose of the network 
  • What membership includes 
  • How the quarterly cornerstone meetings work 
  • How bespoke value delivery works 
  • How we deliver demonstrable value to you 
  • Annual member investment